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Extrapyramidal signs frequently accompany Alzheimer’s disease (AD), but the pathological substrate remains unknown. 
Clinical and postmortem information from patients with AD, Parkinson’s disease, or progressive supranuclear palsy and 
control subjects seen at a large tertiary medical center between 1989 and 1994 was examined. AD patients who had taken 
neuroleptics and AD brains that also contained Lewy bodies were excluded. The presence of extrapyramidal signs was 
determined using the Unified Parkinson’s Disease Rating Scale. Sections of basal ganglia, subthalamic nucleus, and 
substantia nigra were examined for neurofibrillary tangles and neuropil threads and the nigra for neuronal numbers. 
Patients with AD (with or without extrapyramidal signs) did not show neuronal loss in the nigra compared to control 
subjects, while both Parkinson’s disease and progressive supranuclear palsy brains showed marked depletion. The num- 
ber of neurofibrillary tangles and neuropil threads was increased in AD (with or without extrapyramidal signs) nigra 
compared to control tissue, and also in progressive supranuclear palsy nigra, but not Parkinson’s disease nigra. The 
numbers of nigral neurofibrillary tangles and neuropil threads were positively related to extrapyramidal signs in AD. 
There were no correlations between tangles and threads in the basal ganglia or subthalamic nucleus and extrapyramidal 
signs in AD. Thus, extrapyramidal signs in AD correlate best with tangle pathology in the nigra and do not require the 
concomitant presence of Lewy bodies. 
Liu Y, Stern Y, Chun MR, Jacobs DM, Yau P, Goldman JE. Pathological correlates 
of extrapyramidal signs in Alzheimer’s disease. Ann Neurol 1997;4 1:368 -374 
Extrapyramidal signs (EPSs) frequently accompany Alz- 
heimer‘s disease (AD) [l-41 and their presence is re- 
lated to more rapid cognitive and functional decline 
and earlier death [I]. The anatomical and pathological 
basis for EPSs in AD has not been clear, however. The 
possibility that EPSs may result from concomitant Par- 
kinson’s disease (PD) is suggested by the presence of 
L e y  bodies in the substantia nigra of many AD pa- 
tients. For example, pathological analyses of AD series 
revealed Lewy body changes in 25 to 55% of AD pa- 
tients [5-81. The variation among studies is no doubt 
related in large part to differences in the specific pa- 
tient populations examined. 
Nevertheless, AD patients without Lewy bodies do 
manifest EPSs [8]. Studies of the neuropathology that 
could underlie EPSs in AD have been confounded by 
the treatment of many patients with neuroleptic med- 
ication, by only a qualitative analysis of nigral pathol- 
ogy, and by only cursory descriptions of nigral changes. 
Nigral neuropathology is indeed present in AD in the 
form of neurofibrillary tangles (NFTs), as noted in sev- 
eral studies [G, 9, 101, but has not been described in 
detail using a variety of sensitive detection methods. 
The numbers of nigral neurons, assessed either qualita- 
tively [2, 4,  81 or quantitatively [ 3 ] ,  appear to be nor- 
mal or near normal, with at most only a mild decrease, 
and thus represent a considerable difference from the 
marked neuronal depletion seen in I’D. Furthermore, 
normal levels of tyrosine hydroxylase, dopamine D, re- 
ceptor, and dopamine transporter are found in the AD 
nigra [I  11, consistent with a normal or near-normal 
neuronal population. Despite this relatively normal 
neuronal component, there is a loss of dopamine trans- 
porter in the striata of individuals with AD and par- 
kinsonism [ I l l .  This loss implies that there are im- 
portant pathological changes in the nigrostriatal projec- 
tions. 
We reexamined the problem of EPSs in AD by ex- 
amining the brains of patients with clinical and patho- 
logically confirmed AD, some of whom manifested 
EPSs. To  isolate AD changes from rhose of PD, we 
excluded AD patients with Lewy bodies from our anal- 
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ysis. We also compared the numbers of neuronal cells, 
NFTs, and neuropil threads (NPTs) in AD with those 
i n  PD and progressive supranuclear palsy (PSP). 
Research Design and Methods 
Subjects 
AD CASE SELECTION. Patients with a diagnosis of AD were 
selected from all autopsy reports at Columbia Presbyterian 
Medical Center from 1989 through 1994. We then exam- 
ined neurological and neuropsychological clinical records to 
evaluate the presence or absence of EPSs. The inclusion and 
exclusion criteria for AD cases were as follows: 
All included individuals had been examined at Columbia 
by members of the neurology staff. Each subject met Na- 
tional Institute of Neurological and Communicative Disor- 
ders and Stroke-Alzheimer‘s Disease and Related Disorders 
Association (NINCDS-ADRDA) criteria for probable AD 
during life [12], EPSs must have been assessed using the 
Unified Parkinson’s Disease Rating Scale (UPDRS) [13, 141, 
and each had neuropathological confirmation of AD (neurit- 
ic plaques and NFTs in numbers to meet the Consortium to 
Establish a Registry for Alzheimer’s Disease [CERAD] crite- 
ria [15]). The interval between the last clinical examination 
and death generally was less than 1 year (8.5 months on 
average). 
Exclusion criteria included a history of stroke, schizophre- 
nia, motor neuron disease, presence of any central nervous 
system (CNS) infections, or clinical and pathological diagno- 
sis of PD ( L e y  bodies in the substantia nigra). Patients who 
were taking neuroleptic medication at any time were also ex- 
cluded, to rule out the possibility of drug-induced EPSs. 
AD patients were separated into two groups, based on the 
presence or absence of EPSs. Significant EPSs were consid- 
ered present if there was any resting tremor ( 1  + or greater) 
or 2+ rigidity; these ratings have been shown to be highly 
reliable [ 141. Speech, facial expression, and bradykinesia were 
not included because ratings of these signs are less reliable. 
taken from the level of the anterior limb of the internal cap- 
sule and the level of the anterior thalamic nuclei separately. 
Sections of midfrontal, superior temporal, and inferior pari- 
etal regions of the cortex and of the hippocampus were also 
examined. Tissue blocks were processed through paraffin em- 
bedding. Sections were stained with hematoxylin and cosin 
for general screening. In addition, sections of the substantia 
nigra, basal ganglia, and subthalamic nucleus were stained 
with the Gallyas silver method and with paired helical fila- 
ments (PHFs) and ALZ-50 antibodies, all of which gave sim- 
ilar results, for recognizing NFTs and neuropil-like threads 
[16-181. The NFT and N P T  counts in the nigra were ob- 
tained in four standard 1-mm2 areas (see below). The density 
of NPTs was determined by examining each of the four 
squares in the nigra and counting NPTs in the densest 10X 
microscope field therein. The maximal NPT density was 
then expressed on a four-point scale (0 = absent, 1 = sparse 
[l-5 profiles/lOX microscope field], 2 = moderate [5-15 
profiles], 3 = severe [>I5 profiles; the photomicrograph in 
Fig 3 illustrates a “severe” NPT pathology]). NFT density 
was expressed as the average number per square in all four 
areas per nigra. We used an antiubiquitin antibody [19] to 
recognize Lewy bodies. Neither this nor hematoxylin and eo- 
sin stains revealed Lewy bodies in the nigra or locus ceruleus, 
basal forebrain, hypothalamus, or neocortex in any of the 
AD brains. NFTs and NPTs were counted over the entire 
sectional areas of the basal ganglia and subthalamic nucleus. 
To  quantitate numbers of neuronal profiles in the pars 
compacta of the substantia nigra, we divided the nigra into 
quarters, and placed a square of 1-mm2 area in each quarter, 
similar to the analysis carried out by Rinne and colleagues 
[3] (Fig 1). We counted all neuronal perikarya recognizable 
Fig 1. Transverse section of the substantia nigra at the level of 
the superior colliculus (sc) and caudal red nucleus (rn). The 
squares show the areas where neuronal, neurojbrillary tangle, 
and neuropil thread densities were studied. la = medial; 
Ib = midmedial; 11 and III = midLatera1 and latei,al areas. 
CONTROL SELECTION. Control cases were obtained by 
sampling all autopsy cases at the medical center during the 
same period. Control subjects were matched ro the AD pa- 
tients for age and sex, and had a medical evaluation extensive 
enough to document general medical, neurological, and cog- 
nitive status. A neurologist (M. R. C.) reviewed each control 
subject’s medical record to ensure that criteria for dementia 
and EPSs were not present for 5 years prior to death. 
Brains from 11 PD and 9 PSP patients were obtained dur- 
ing the same years (1989-1994) and were selected from the 
files of the Neuropathology Unit of the Columbia Presbyte- 
rian Medical Center. Reports and slides from these cases 
were reviewed for accuracy of final diagnosis. 
Neuropatbological Evaluations 
The right hemibrain was sectioned coronally and samples 
were taken from the substantia nigra at the level of the red 
nucleus and superior colliculus. In 4 AD and 4 control 
brains, samples of the nigra were also taken at a more caudal 
peduncle. The basal ganglia and subthalamic nucleus were 
level, at the point of decussation of the superior cerebellar Ia  Ib 11 111 
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by pigment in each area. Profiles falling on grid lines were 
treated according to Gundersen's rule [3]. 
This method of counting allows one to determine the 
numbers of neuronal profiles in four standai-d areas of the 
nigra, yielding what is essentially a profile density. The rela- 
tionship of this number to the actual numbers of nigral neu- 
rons was nor determined. Change in the size of neuron pro- 
files affects their likelihood of being counted within a 
section, and therefore alters the relationship between the 
number of counted profiles and the actual number of neu- 
rons present [20].  We therefore assessed neuron size in AD 
and control brains by measuring their cross-sectional area. 
This was done by coupling a Nikon Labophot microscope to 
a Dage 81 Series video camera, digitizing profiles under a 
60X objective, and determining area using a Loats Associates 
Inquiry image analysis system. 
All autopsy evaluations were based on pathological diag- 
nostic criteria (CERAD criteria). Both neuropathologists 
(Y. L., J .  E. G.) examined those neuronal changes in the 
substantia nigra. 
The PD patients showed few pathological changes of the 
AD rype (4 with NFTs only in the entorhinal cortex, layer 
11; only 1 with few NFTs in CA1 hippocampus; none with 
neocortical NFTs; 10 with rare, diffuse amyloid plaques in 
the neocortex; and 1 with moderate, diffuse and neuritic 
plaques in the neocortex). 
























































































































































" Sign noted on one occasion, bur not on  subsequent evaluations. 
- = no signs; + = slight signs; + + = moderate to severe signs. 
Data Analysis 
The differences between individual patient groups were eval- 
uated by independent samples t test or by categorical data x2 
statistics. Conditional logistic regression techniques for 
matched studies were used to estimate the association be- 
tween AD (with [ +] or without [ -1 EPS) and neuropatho- 
logical findings. Analyses were controlled for age and sex. 
One-way analysis of variance was used to evaluate the differ- 
ences in the magnitude of nigral degenerative changes among 
the control, AD, PD, and PSP groups. 
Results 
Chical Features o f  AD Patients 
Eighteen of the 28 AD patients met criteria for the 
presence of EPSs (Table 1). These 18 patients had 
scores of moderate to severe on rigidity or tremor (AD/ 
E X + ) .  Seventeen of them displayed severe neck, limb, 
o r  postural rigidity, and 1 patient had slight rigidity 
and a resting tremor. No individual had an isolated 
rigidity of the neck, arm, or leg. Action or  postural 
tremors were not used as EPS criteria. The 10 other 
patients had mild or no EPSs. One of these 10 patients 
had a score of 2 for bradykinesia but only had an oc- 
casional tremor. Demographic and clinical characteris- 
tics of control and AD groups are shown in Table 2. 
t Tests revealed that AD (with and without EPSs) 
patients were significantly older than the control 
group ( p  = O.O2) ,  but there were no differences in age, 
gender, or the duration of AD between the AD/EPS- 
and AD/EPS+ groups. 
To determine whether EPSs occur at a late stage of 
AD, we looked for associations between the Clinical 
Dementia Rating (CDR) score (range, 0-5, with 5 be- 
ing most severe) and the presence of EPSs. At the ini- 
tial evaluation at Columbia Presbyterian Medical Cen- 
ter, 10 patients displayed EPSs, while 18 others did 
not. Eight of the 18 eventually did develop EPSs; 10 
never did. At the initial evaluation, the 10 individuals 
with EPSs had a mean CDR score of 2.40 (scores rang- 
ing from 0-5), whereas the mean CDR score of the 8 
patients without EPSs who would eventually develop 
EPS was 1.25 (scores ranging from 1-2) ( p  = 0.06). 
Of the 18 patients who had or developed EPSs, I0  had 
Table 2. Age, Sex, and Clinical Variables of the AD Patierits 
Duration 
Groups Age (yr)" Sex (F/M) EPS"/AD of AD 




75.3 2 10.9 13/15 18/28 6.8 i 3.3 
'I Mean 2 standard deviation. 
" According to Unified Parkinson's Disease Rating Scale (UPDRS). 
AD = Alzheimer's disease; F = female; M = male; EPS = extra- 
pyramidal sign. 
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Fig 2. Representative photomicrographs o f  the medial (la) region o f  the substantia nigra. (A) Control. (B) AD. (0 Parkinson i 
disease. (0) Progressive supranuclear palry. (X 80.) 
CDR scores of 0 to 2 when EPSs were first found, and 
8 had Scores of 3 to 5 ;  the average CDR Score at the 
time when EPSs were initially observed was 2-33 5 
Fig 3. Gallyas silver staining of the substantia nigra j o r n  the 
brain of an AD patient with extrapyramidal signs shows neu- 
rowheads). This would correspond to a rating o f  3 (severe) for 
neuropil threads. (X 400 befire 53% reduction.) 
1.24 (standard deviation [SD]). patients but one rofibrilkl' tangles (arrows) and many neuropil &eadJ (ar- 
were ambulatory at the first determination of EPS. 
Comparison of  Nigral Degenerative Changes 
There were two comparisons in this study: The first 
was a comparison among AD patients as an entire 
group, the elderly control group, PD patients, and PSI' 
patients; the second was a comparison between AD/ 
EPS- and AD/EPS+ groups. The three nigral vari- 
ables assayed were neuronal profile number, NFTs, and 
NPTs (Figs 2, 3) .  
We compared the numbers of neuronal profiles in 
control, AD, PD, and PSP brains using a one-way 
analysis of variance (Fig 4).  The number of neuronal 
profiles was not significantly reduced in the AD group 
compared to the control group (1,156.2 i 352.0 
[mean 2 SD] in AD, 1,314.2 +_ 385.4 in controls, 
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Fig 4. Analysis of numbers o f  nigral neurons in each o f  tbe 
f iur  test area in control, all AD, Parkinson j disease (PO), 
and progressive supranuclear pahy (PSI') brains. < 0.5; 
*% < 0.0001. 
p = 0.5), but there was a severe loss in PD and PSP 
compared to control brains (563.4 2 134.6 in PD, 
406.6 t 83.4 in PSP, p < 0.0001). When AD pa- 
tients were separated into AD/EPS- (n = 10) and 
AD/EPS+ (n = 18) subgroups, there was still no sig- 
nificant difference between the numbers of nigral neu- 
ronal profiles in AD/EPS+ patients and in controls 
( p  = 0.4). 
Counting neuronal profiles in the above-described 
manner thus revealed a 57% average decrease in PD 
brains, compared to control brains, similar to the 66% 
decrease in nigral neurons in PD brains determined 
stereologically [21]. As noted in the methods section, 
this type of counting can be biased by changes in the 
sizes of neurons. We do not know whether there was a 
significant decrease in the mean volume of nigral neu- 
rons in AD compared to control brains (volume mea- 
surements of pigmented nigral neurons in PD show 
only a modest decrease [22]). We therefore measured 
the cross-sectional area of pigmented neurons in con- 
trol and AD brains, using sections that intersect the 
nucleolus. In analyzing 9 to 10 randomly selected neu- 
rons per nigra from 10 control and 10 AD brains, we 
found no significant differences between the areas of 
neuronal profiles in control and AD brains (respective- 
ly, 790.7 2 265.1 km2, mean +. SD, n = 103, vs 
660.5 t 296.0 pm2, mean ? SD, n = 94, p = 0.08), 
suggesting that size differences did not bias our profile 
counts. 
In contrast with the normal neuronal numbers in 
AD, the entire AD group showed significantly higher 
numbers of NFTs and NPTs than did the control 
group ( p  < 0.0001) (Fig 5 ) .  There was no difference 
between AD and PSP in the numbers of NFTs and 
NPTs. There were no NFTs in the PD nigra, but we 
did find NPTs, although the numbers were less than 
( I  
r 
* *  
LI Contiol 
t- A D  
m PD 
i t  
] I  ** 
I 
0 I i  - - 
I 
PSP 
Denvty of NPTs # of NFTs 
Fig 5. Analysis of nigral neurofibrillary tangles (NFTs) and 
neuropil threads (NPTs) in control, AD, Pa'dvkinron j disease 
(I'D), and progressive supranuclear palsy (PSI') brains, con- 
ducted over all four test areas. Mean values ? standard error 
of mean for NPT density and NFT numbers are given, calcu- 
lated as described in the methods section. *p < 0.03; **p < 
0.0001. 
those in AD nigra ( p  < 0.03). In a comparison within 
the AD group, there were significantly larger numbers 
of NFTs and NPTs in the AD/EPS+ group than in 
the AD/EPS- group (for NFTs, x2 = 7.9, p < 0.05; 
for NPTs, x2 = 7.6, p < 0.04) (Fig 6).  
In 4 AD/EPS+ and 4 control nigras, we examined 
neuronal profiles, NFTs, and NPTs at a more caudal 
level and compared these values to those at the more 
rostra1 level in the same brain. In all brains, there were 
no significant differences ( p  = 0.25 for neuronal pro- 
file numbers in control and p = 0.15 for AD brains; 
p = 0.64 for NFTs and p = 0.42 for NPTs). 
Comparison of Pathological Changes in Basal 
Ganglid and Subthalamic Nucleus 
All (n = 9) PSP brains showed NFTs and NPTs in the 
subthalamic nucleus and basal ganglia, with widespread 
Fig 6 Analysis of nigral neurojibrillary tangles (NFTs) and 
neuropil threads (NPTs) in AD with extrapyramidal signs 
(ADIEPS +) and without extrapyramidal signs (ADIEPS-). 
Data are displayed as in Figure 5. *p < 0.05; **p < 0.04. 
401i c 
3 5 0  1 
* 
I 
3 0 0  1 
2 5 0  1- 
050 loo 1 , 
Density of NPTs #f ofNFTs 
ADEPS- 
El AD/EPS+ 
- A  
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neuronal loss. There were no NFTs or NPTs in the 
putamen, globus pallidus, and subthalamic nucleus in 
control or PD brains. However, there were mild to 
moderate numbers of NPTs in the putamen and glo- 
bus pallidus in AD/EPS+ (3/18) and ADIEPS- (1/ 
10) brains. 
Comparison of Changes in Cortex in AD with and 
without Extrapyramidal Signs 
We examined sections of frontal, parietal, superior 
temporal, and striate cortex and hippocampus in all 
AD patients by semiquantitative criteria [ 151. There 
were no differences in the numbers of amyloid plaques 
(neuritic or diffuse), NFTs, or NPTs between AD pa- 
tients with and those without EPS. 
Discussion 
The frequency of nigral NFTs and NPTs was signifi- 
cantly higher among AD patients with EPS compared 
to those without EPS. These pathological changes were 
found in both the lateral and medial parts of the sub- 
stantia nigra, suggesting that the degenerative process 
in the nigra affects the dopaminergic afferent pathway 
not only to the putamen but also to the caudate nu- 
cleus [3].  Neurons in the medial part of the nigra to- 
gether with the neurons of ventral tegmental area are 
known to project to the limbic and cortical areas [15] 
and may be involved in the cognitive impairment in 
AD. Because we excluded patients with Lewy bodies to 
isolate the AD pathology from that of PD, there was 
no coexistent PD pathology to account for the nigral 
degenerative changes. 
The topography of degenerative changes in the sub- 
stantia nigra has been studied in other neurodegenera- 
tive disorders such as PD and PSP. The loss of neurons 
from the substantia nigra was more conspicuous in PD 
and PSP than in AD. However, far more NFTs were 
seen in the AD brains than in the PD brains, suggest- 
ing that this nigral degenerative change is primarily in- 
volved in AD. 
The presence of EPSs in AD was not associated with 
neuronal loss in the substantia nigra, when compared 
with control cases and with the profound losses in PD 
and PSP. This observation is consistent with previous 
reports of normal nigral populations in AD [5-81 and 
normal levels of tyrosine hydroxylase, D, receptors, 
and dopamine transporter in AD, with and without 
parkinsonism [I 11. Thus, the lack of cell loss in AD/ 
EPS+ suggests that if nigral dysfunction is related to 
EPSs, then the surviving neurons do not function nor- 
mally. The cytoskeletal pathology we observed in the 
AD nigra may well be a sign of such dysfunction. For 
example, altered axonal transport, either due to the cy- 
toskeletal pathology or reflected in the cytoskeletal pa- 
thology, could in turn alter synaptic levels of molecules 
required for dopaminergic function, such as dopamine 
transporter (the loss of which was noted by Murray 
and coauthors [ 1 I]). 
In this study, we compared nigral pathology in AD, 
PD, and PSP brains to normal brains, paying particular 
attention to the changes that might correlate with 
EPSs. Our analysis was based on chart reviews of AD, 
PD, and PSP patients evaluated during life by neurol- 
ogists and then a postmortem pathological study. We 
are not able to rule out the possibility that some of the 
control group did develop EPSs that were simply not 
detected or not mentioned. However, a pathological 
analysis of control cases did not show any to have de- 
veloped PD, PSP, or AD. 
Differences in the speed of cognitive and functional 
decline are important factors for prognosis in patients 
with AD. Reports in the literature linked faster deteri- 
oration in AD to the presence of EPSs [ 1, 231. Some 
studies [6, 9, 101 used neuropathological methods to 
address this issue, but the results were inconsistent and 
did not relate specific AD pathology to the clinical 
EPSs. In this study, we used autopsy-confirmed AD 
cases to explore a possible association between nigral 
degenerative changes and EPSs in AD. The findings 
suggest that degenerative changes in the substantia 
nigra, especially NFTs and NPTs, represent correlates 
of EPSs. 
We did not find a strong association between the 
CDR scales of the AD patients and the presence of 
EPSs or between the extent of pathology in the neo- 
cortex and substantia nigra. Thus, EPSs do not appear 
to be unique to the late stages of AD. That some pa- 
tients with AD never develop EPSs also argues that 
cortical pathology and nigral pathology can progress 
independently. Why the nigra develops pathological 
changes in some individuals is not clear. 
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